Brief: Novartis Receives Health Canada Approval For Fabhalta Oral Treatment For Adults With C3G
01/05/2026 19:11
May 1 (Reuters) - Novartis Pharmaceuticals Canada: NOVARTIS RECEIVES HEALTH CANADA APPROVAL FOR FABHALTA® ORAL TREATMENT FOR ADULTS WITH C3G NOVARTIS PHARMACEUTICALS CANADA: FABHALTA IS AVAILABLE IN CANADA THROUGH A CONTROLLED DISTRIBUTION PROGRAM Source text: ID:nCNWgV9SPa Further company coverage: NOVN.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'